A method for inhibiting and/or treating ebolavirus (EBOV) infection comprising administering a therapeutically effective amount of Ezetimibe or its derivatives alone, or in combination with, a compound which mediates allosteric modulation of beta 1 integrin. The compound which mediates allosteric modulation of beta 1 integrin may be an antibody that binds to an epitope present on the extracellular domain of beta 1 integrin such as the hybrid domain. The antibody may be HUTS21 or B44. Also claimed is a compound that binds to at least one epitope on the extracellular domain of beta integrin 1 and an assay method for identifying compounds for use in the inhibition and/or treatment of EBOV comprising screening candidate compounds for the ability to allosterically modify beta 1 integrin and compounds which affect sphingomyelinase function.
